|
|
|||||||||||
|
Funding Opportunities | Cancer Cell Biology Track | SCCCB Pre-doctoral Fellowship | Seminars | News | Related Links | Site Index |
|||||||||||
The main focus in Dr. Xie's laboratory is to investigate signal transduction of the hedgehog pathway and its role in the development of cancers. This pathway was initially discovered by two Nobel Laureates Dr. E. Wieschaus and Dr. C. Nusslein-Volhard in Drosophila in early 80's. The hedgehog signaling is a master regulator for cell differentiation, tissue polarity and cell proliferation. In the last few years, Dr. Xie and his colleagues have discovered two members of this pathway, patched and smoothened, being responsible for the development of basal cell carcinomas (BCCs) and medulloblastomas. BCCs, the most common cancer in Caucasians with the lifetime risk of one in three, are generally only locally invasive and rarely metastasized. Medulloblastomas, a primitive neuroectodermal tumor of cerebellum, account for 20% incidence of pediatric brain tumors, progress rapidly into malignant tumors. In these cancers, this pathway is activated by either inactivated mutations of patched or activated mutations of smoothened. Recent data indicate that hedgehog signaling is activated in about 30% extracutaneous tumors, including gastrointestinal, prostate and breast cancers. Whereas the biological consequences of dysregulation of this pathway are well established, the molecular mechanism of the signal transduction is still poorly understood. They are taking three approaches to understand the mechanism by which activation of the hedgehog pathway contributes to cancers. First, the activating form of smoothened or the downstream molecule Gli is used as a "biological probe" for the identification, isolation and functional dissection of molecular components that collaborate to regulate the signaling pathway. Second, they are studying the interaction of this pathway with other signaling pathways in human cancers. Third, mouse models are being used to understand activation of the hedgehog pathway in vivo. Ultimately, they hope to find ways to inhibit this pathway with small molecules in relevant human cancers.
Lam CW, Xie J, To KF, Lee KC, Yuen WF, Lim PL, Chan YS, Tong SF, McCormick FA. frequent
activated smoothened mutation in sporadic basal cell carcinomas. Oncogene 18:833-837, 1999. Athar* M, Li C-X, Chi S, Tang X, Kim A-L, Norris BA, Tyring SK, Kopelovich L, Epstein EH Jr, Bickers DR, Xie* J. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through induction of fas expression and apoptosis (The first two authors contribute equally). Cancer Research 60:7545-52, 2004. [Paper in PDF format] Haque AK, Au W, Zwischenberger JB, Norris B, Ginzel AW, Jones DV, Xie J. Association of patient smoking history, cyp2E1 polymorphism and p53 expression with patient survival in non-small cell lung cancer. American Immunohistochemistry and Molecular Morphology 12:315-322, 2004. [Paper in PDF Format] Ma XL, Sun HJ, Wang YS, Huang SH, Xie J, Zhang HW. Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol. 2006 Jul 7;12(25):3965-9. He J, Sheng T, Stelter A, Li C, Zhang X, Sinha M, Luxon B, Xie J. Suppressing Wnt signaling by the hedgehog pathway through sFRP-1. J Biol Chem. 2006 Nov 24; 281(47):35598-602, 2006 Oct 10; [Epub ahead of print]. Ji Z, Mei FC, Xie J, Cheng X., Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells. J Biol Chem. 282(19):14048-55, 2007.
|
![]()
Home | Mission | Investigators
| Transgenic Mouse Facility |
PCR Core Facility |
Human Tumor Bank | Career
Opps
Funding Opportunities |
Cancer Cell Biology
Track | SCCCB Pre-doctoral Fellowship
| Seminars |
News | Related Links |
Site Index
This site
published by John Helms
for
the Sealy Center for Cancer Cell Biology.
Copyright © 2002 The
University of Texas Medical BranchPlease review our
privacy policy and
Internet guidelines
Last Revised: January 18, 2008